Safety and Efficacy Study Using Rexin-G for Breast Cancer
NCT00505271
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
20
Enrollment
INDUSTRY
Sponsor class
Conditions
Breast Cancer
Interventions
GENETIC:
Rexin-G
Sponsor
Epeius Biotechnologies